Evidence map›Paper›PMID 38646594›Full record

ArticleRSC pharmaceutics2024

Molecular structure of ketoprofen-polyvinylpyrrolidone solid dispersions prepared by different amorphization methods.

Stephen K Wilke, Chris J Benmore, Vrishank Menon, Dan Smith, Stephen R Byrn, Richard Weber

Abstract read
In one paragraph

Article in RSC pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephen K WilkeMaterials Development, Inc. Evanston 825 Chicago Ave IL 60202 USA swilke@matsdev.com.ORCID https://orcid.org/0000-0003-4674-7049
Chris J BenmoreX-Ray Science Division, Advanced Photon Source, Argonne National Laboratory Argonne IL 60439 USA.ORCID https://orcid.org/0000-0001-7007-7749
Vrishank MenonMaterials Development, Inc. Evanston 825 Chicago Ave IL 60202 USA swilke@matsdev.com.
Dan SmithImproved Pharma West Lafayette IN 47906 USA.
Stephen R ByrnImproved Pharma West Lafayette IN 47906 USA.
Richard WeberMaterials Development, Inc. Evanston 825 Chicago Ave IL 60202 USA swilke@matsdev.com.

Funding

Amorphous Pharmaceutical Product Development Using Containerless MethodsR44GM117701 · NIGMS · MATERIALS DEVELOPMENT, INC. · PI WEBER, RICHARD JOHANN · 2019 to 2020
$992k
NIGMS NIH HHS R44 GM117701
6 · The paper itself

Abstract

Amorphous solid dispersions (ASDs) are a widely studied formulation approach for improving the bioavailability of poorly water-soluble pharmaceuticals. Yet, a complete understanding remains lacking for how specific processing methods may influence ASDs' molecular structure. We prepare ketoprofen/polyvinylpyrrolidone (KTP/PVP) ASDs, ranging from 0-75 wt% KTP, using five different amorphization techniques: melt quenching, rotary evaporation with vacuum drying, spray drying, and acoustic levitation with either a premixed solution or

Identifiers

PMID38646594
PMCPMC11024667

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.